20 February, 2015. Biotecnol Ltd of UK and BioArtic Neuroscience AB of Sweden, entered into a collaboration to develop a new in-vivo diagnostic tool for Alzheimer’s disease (AD) based on Biotecnol’s Tribody™ technolgy and BioArtic’s anti-amyloid beta (Aβ) antibodies. The research work will be conducted in the laboratories of Lars Lannfelt, Dept. of Public Health/Geriatrics at Uppsala University, Sweden.
Dr Neill Mackenzie , CBO Biotecnol commented, “We are very pleased that such a prestigious group has chosen our technology to solve the problem of delivering antibodies across the blood-brain barrier.We are looking forward to seeing some exciting results from the research”
Dr Pär Gellerfors, Founder of BioArctic, “We believe that this research will lead to a new in-vivo diagnostic tool for Alzheimer’s disease. The Tribody™ format that Biotecnol have developed offers potential solutions to the problem that we could not find in other technologies”
About the Tribody™ format
Tribody™ molecules are multi-specific antibodies, produced by established recombinant DNA technology methods, which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional functionality can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binding sites and can combine different functions all in one single molecule.
About Biotecnol Limited
Biotecnol Limited is an immuno-oncology company developing innovative immune-function activating and immune-function modulation approaches for treating cancer. These approaches seek to recruit or to modulate the body’s own immune defences such as T cells and NK cells to kill tumours. Biotecnol multi-specific antibody products are based on its proprietary Tribody™ and Trisoma® platforms, which are comprised of a variety of formats with key properties. Under the Trisoma® platform, Biotecnol has developed a novel format known as Targeted T-cell Engaging Agonistic Response Modifiers or iChecks™.These products aim at improving tumour cell dependent T-cell or NK-cell activation. The iCheck™ formats are expected to achieve a more localized immune-function activation and obtain less or no systemic toxicity, whilst having an increased therapeutic index.These are potentially safer and more effective drugs for treating highly-heterogeneous and highly-aggressive solid tumours.
About BioArctic Neuroscience
BioArctic Neuroscience AB is a biopharmaceutical company carrying out research and development for new treatments of disorders in the nervous system. The company, which was founded in 2003, has a proprietary technology for therapeutic monoclonal antibodies, for the treatment of Alzheimer’s disease, Parkinson’s disease and other related neurological disorders. The most advanced project, BAN2401, is currently in late clinical development in early Alzheimer’s disease together with Eisai Co. Ltd. The company in-licensed 2008 a novel innovative treatment for spinal cord injuries, which now is progressing into clinical development. The company’s business model is to form strategic research alliances, joint ventures or license agreements with pharmaceutical industries and bring its drug candidates to the world market. The company, which is headquartered in Stockholm, has received early venture capital from Karolinska Development AB and Uppsala Holding AB. www.bioarctic.se
Back to news